Macakurzin C Derivatives as a Novel Pharmacophore for Pan-Peroxisome Proliferator-Activated Receptor Modulator

The natural flavonoid macakurzin C (1) exhibited adiponectin biosynthesis-inducing activity during adipogenesis in human bone marrow mesenchymal stem cells and its molecular mechanism was directly associated with a pan-peroxisome proliferator-activated receptor (PPAR) modulator affecting all three PPAR subtypes α, γ, and δ. In this study, increases in adiponectin biosynthesis-inducing activity by macakurzin C derivatives (2–7) were studied. The most potent adiponectin biosynthesis-inducing compound 6, macakurzin C 3,5-dimethylether, was elucidated as a dual PPARα/γ modulator. Compound 6 may exhibit the most potent activity because of the antagonistic relationship between PPARδ and PPARγ. Docking studies revealed that the O-methylation of macakurzin C to generate compound 6 significantly disrupted PPARδ binding. Compound 6 has therapeutic potential in hypoadiponectinemia-related metabolic diseases.

[1]  Ji Won Kim,et al.  Discovery and Structure-Activity Relationships of Novel Template, Truncated 1'-Homologated Adenosine Derivatives as Pure Dual PPARγ/δ Modulators. , 2020, Journal of medicinal chemistry.

[2]  S. Shin,et al.  Diallyl Biphenyl-Type Neolignans Have a Pharmacophore of PPARα/γ Dual Modulators , 2020, Biomolecules & therapeutics.

[3]  L. Jeong,et al.  Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor δ. , 2019, Bioorganic & medicinal chemistry.

[4]  C. Mantzoros,et al.  Adiponectin and leptin in the diagnosis and therapy of NAFLD. , 2019, Metabolism: clinical and experimental.

[5]  C. Mantzoros,et al.  Obesity and cancer risk: Emerging biological mechanisms and perspectives. , 2019, Metabolism: clinical and experimental.

[6]  K. Jacobson,et al.  Polypharmacology of N6-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Potential. , 2017, Journal of medicinal chemistry.

[7]  Nikolai Petrovsky,et al.  X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs. , 2017, Biochimica et biophysica acta. General subjects.

[8]  M. Bowman,et al.  Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ , 2017, Proceedings of the National Academy of Sciences.

[9]  A. Lavecchia,et al.  Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode , 2016, Scientific Reports.

[10]  Sun-Young Chang,et al.  A newly synthesized macakurzin C-derivative attenuates acute and chronic skin inflammation: The Nrf2/heme oxygenase signaling as a potential target. , 2016, Toxicology and applied pharmacology.

[11]  P. Scherer,et al.  Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. , 2016, Cell metabolism.

[12]  J. Bruning,et al.  Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism , 2015, PPAR research.

[13]  T. Kamarul,et al.  The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin. , 2015, Life sciences.

[14]  Seung-Hoon Baek,et al.  Synthesis and Biological Evaluation of Acetylcholinesterase Inhibitor Macakurzin C and Its Derivatives , 2015, Synlett : Accounts and Rapid Communications in Synthetic Organic Chemistry.

[15]  R. Bauer,et al.  Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review , 2014, Biochemical pharmacology.

[16]  Seung‐Yong Seo,et al.  Total Synthesis of Acetylcholinesterase Inhibitor Macakurzin C , 2014, Synlett.

[17]  Manabu T. Nakamura,et al.  Regulation of energy metabolism by long-chain fatty acids. , 2014, Progress in lipid research.

[18]  Clarisse G. Ricci,et al.  Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization. , 2013, Journal of molecular biology.

[19]  D. Kojetin,et al.  Small Molecule Modulation of Nuclear Receptor Conformational Dynamics: Implications for Function and Drug Discovery , 2013, Molecular Pharmacology.

[20]  M. Litaudon,et al.  Acetylcholinesterase inhibitors from the leaves of Macaranga kurzii. , 2012, Journal of natural products.

[21]  C. Glass,et al.  PPARs and lipid ligands in inflammation and metabolism. , 2011, Chemical reviews.

[22]  J. Klein,et al.  The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses. , 2010, The Journal of endocrinology.

[23]  Sun Mi Park,et al.  (-)-Catechin promotes adipocyte differentiation in human bone marrow mesenchymal stem cells through PPAR gamma transactivation. , 2009, Biochemical pharmacology.

[24]  Scott A. Busby,et al.  Partial agonists activate PPARgamma using a helix 12 independent mechanism. , 2007, Structure.

[25]  S. Lippman,et al.  Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity , 2006, Oncogene.

[26]  L. Moore,et al.  Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.